|Home | About | Journals | Submit | Contact Us | Français|
Congenital diaphragmatic hernia (CDH) is a common and well-studied birth defect. The etiology of most cases remains unknown but increasing evidence points to genetic causation. The data supporting genetic etiologies which are detailed below include the association of CDH with recurring chromosome abnormalities, the existence of CDH-multiplex families, and the co-occurrence of CDH with additional congenital malformations.
Congenital diaphragmatic hernia (CDH) is a common, dramatic, and often fatal birth defect. It is not surprising that CDH has long been the focus of scrutiny, with hand-drawn illustrations of diaphragmatic defects dating back over 500 years. There are an abundance of papers reporting on surgical techniques, management of common co-existing medical problems such as pulmonary hypoplasia and pulmonary hypertension, complications for long-term survivors, and imaging modalities for prenatal diagnosis and prognostication. The number of publications on “congenital diaphragmatic hernia” listed in PubMed has exploded in the last 15 years, in part attributable to methodological advances that permit genetic dissection of complex birth defects (Fig. 1).
A congenital diaphragmatic hernia (CDH), sometimes referred to as a congenital diaphragmatic defect, is an abnormality in the integrity of the diaphragm, most often a discontinuity (e.g., “hole”), but sometimes an under-muscularization (e.g., thinning or eventration), in one or more of the diaphragmatic leaflets. CDH arises during prenatal development and the majority of cases can be detected in utero by either ultrasound examination or fetal MRI scanning.
Traditionally, diaphragmatic hernias have been classified according to their presumed anatomic location. Almost 90% of diaphragmatic hernias are reported to involve the posterolateral aspect of the diaphragm; hernias in this location are referred to as Bochdalek hernias. Non-posterolateral or nonBochdalek hernias occur elsewhere, most often in the anterior portion of the diaphragm; usually anterior hernias are called Morgagni hernias. However, close scrutiny of these two supposedly distinct hernia types demonstrates considerable imprecision, since defects do not always localize to either the anterior or to the posterolateral diaphragmatic quadrant [Ackerman et al., 2006a]. A further limitation ofthe anatomic classification system is that diaphragmatic eventration and diaphragmatic hernia, previously classified as unrelated entities, have been reported to co-exist in the same patient, as well as in different affected family members [Mertins, 1952; Varpella and Lehtovaara, 1962; Thomas et al., 1976; Rodgers and Hawks, 1986].
Despite the shortcomings just mentioned, an anatomic system of classification continues to be used, as follows (see Fig. 2):
Sac hernias, as noted above in the discussion of Eventration, are difficult to distinguish from eventrations and are inconsistently defined. Since a sac can co-exist with any of the CDH subtypes defined above, it should not be considered a separate hernia type on its own.
CDH is a common birth defect that is associated with considerable morbidity and mortality. A discussion of epidemiology of CDH is complicated by lack of uniform data collection methods as some studies are population-based, capturing all CDH cases detected early in pregnancy, while others are tertiary-care based capturing only CDH patients who survive delivery and subsequent referral to a specialty center. This discrepancy reveals the “hidden mortality” of CDH, a concept first introduced by Dr. Michael Harrison in 1978 [Skari et al., 2000]. Studies that fail to account for the impact of hidden mortality can demonstrate biased estimates of prevalence, the frequency of “isolated” versus “complex” CDH cases, and of mortality.
The average prevalence of CDH, derived from a meta-analysis of 16 population-based studies, was 1/4000 births [Skari et al., 2000]. Individual study prevalence estimates varied considerably, from a high of 1/1750 [Langham et al., 1996] to a low of 1/5880 [Philip et al., 1991].
Patients with CDH can be divided into two broad phenotypic categories:
Isolated CDH is diagnosed when CDH is the only apparent major malformation. Additional abnormalities, such as pulmonary hypoplasia, intestinal malrotation, and left heart hypoplasia, may co-exist with CDH and can be considered part of a CDH sequence.
Complex CDH is diagnosed when CDH occurs with additional abnormalities either as part of a recognized syndrome, a chromosome abnormality, or a non-syndromic constellation of major malformations (e.g., CDH plus ventriculoseptal defect, or CDH plus cleft lip). Averaging together data from many series complex CDH is found in 30–40% of all cases, though frequencies in individual studies range from a low of 10% to a high of 50%, in part attributable to methodologic differences in case ascertainment (as reviewed in [Skari et al., 2000]. Population-based, as well as prenatally diagnosed-based, studies have more complete ascertainment with ~40% of cases being classified as complex [Torfs et al., 1992; Skari et al., 2000; Dott et al., 2003; Colvin et al., 2005]. On the other hand, studies based at treatment centers usually reflect a biased cohort in that more seriously ill patients are less likely to be transferred for further care (i.e., so-called “hidden mortality”). Accordingly, the frequency of complex CDH cases in these series is lower, on average 23% of all cases [Skari et al., 2000].
There continues to be considerable controversy whether medical and surgical advances have improved survival for infants with CDH. Historically, CDH that was diagnosed in the newborn period was almost uniformly fatal. Hopes for better outcomes followed the introduction of several therapies, such as delayed surgical repair, high frequency ventilation, permissive hypercapnea, extracorporeal membrane oxygenation (ECMO), and nitric oxide.
All studies demonstrate that infants with complex CDH have a higher mortality than those with isolated CDH. This is attributed to a variety of reasons including: higher frequency of spontaneous miscarriage; higher termination rate of pregnancy; more neonatal deaths ascribed to the severity of associated malformations; and the decision not to offer aggressive treatment. A meta-analysis published in 2000 found that the average mortality for cases ascertained prenatally was 75%, for cases ascertained as part of a population-based study was 48%, while for those cases transferred to a treatment center was 45% [Skari et al., 2000]. Several recent studies from tertiary care centers report excellent survival with very low mortality of 10–20% [Downard et al., 2003; Javid et al., 2004]. This remarkable survival rate reflects technical and management expertise gained from a high volume of cases combined with case selection, as would be expected in a referral center cohort. Two recent population-based studies continue to find overall mortality remains greater than 50–60%, despite the introduction of new therapies such as ECMO [Stege et al., 2003; Colvin et al., 2005]. An increasing number of elective terminations also contribute to the persistently high overall CDH mortality.
One small but particularly useful study allows comparison of population-based survival versus “immediate postnatal planned care” survival (equivalent to survival in a tertiary care center) within the same cohort [Betremieux et al., 2004]. Survival for the former was only 40% (12 of 30 cases), with the majority of fatalities occurring in cases without a prenatal diagnosis, or in complex CDH patients who either had a genetic syndrome or additional major malformations. Among those who fulfilled study criteria for receiving “immediate post-natal planned care” survival rose to 92% (11 of12 cases).
Thus, survival can be excellent in cases with isolated CDH, especially if patients are born in, or are stabilized and transferred to, a center with expertise in CDH surgery and medical management. However, survival for all cases recognized to have CDH, including those with complex CDH, does not exceed 50% on average.
Most individuals diagnosed with CDH are the only member of their family to be affected. Thus, CDH typically has been viewed as a “sporadic” birth defect, which has erroneously been equated with “non-genetic”. There is growing evidence supporting genetic causation of CDH, such as genetically modified model organisms, recurring human chromosome abnormalities, and single gene mutations (Table I). A summary of the current evidence supporting genetic etiologies of CDH is presented below.
Many common and seemingly sporadic birth defects are now known to be caused by mutations in one or more genes often in related pathways, or by the multiplicative effects of variations in several genes. Hirschsprung (HSCR) disease is a prime example. Prior to surgical advances that allowed improved survival, scant data demonstrated family clustering of HSCR. Now that survival is routine, many multiplex families are documented. The current understanding of HSCR genetics is considerable, with identification of mutations in the RET proto-oncogene and its ligands, as well as the endothelin B receptor and some of its ligands, among others [Lantieri et al., 2006]. CHARGE syndrome and several forms of congenital heart defects are due to mutations in CHD7 and NKX2.5, respectively [Goldmuntz et al., 2001; Elliott et al., 2003; Vissers et al., 2004]. These precedents suggest that gene defects, either in isolation or as combinatorial gene-environment or gene-gene interactions, are likely to play a significant role in diaphragmatic defect causation, even among “sporadic” cases of CDH. Discovery of a de novo mutation in FOG2 in a lethal case whose only abnormalities on autopsy were a posterior muscularization defect in the eventration-sac hernia spectrum and pulmonary hypoplasia [Ackerman et al., 2005] provides proof of principle.
Reports of several naturally occurring animal models of CDH are consistent with, but not confirmatory of, genetic causation. More compelling evidence derives from mouse genetic models with mutations in single genes such as COUPTFII [You et al., 2005], Fog2 [Ackerman et al., 2005], Slit3 [Liu et al., 2003; Yuan et al., 2003], Wt1 [Kreidberg et al., 1993], and Gata4 [Jay et al., 2006]. These model organisms are reviewed in greater detail in the article by Ackerman and Greer, in this monograph.
The frequency of CDH in several single gene disorders is greater than expected by chance alone, such as in Brachman-de Lange [Cunniff et al., 1993; Pankau and Janig, 1993; Marino et al., 2002], Craniofronto-nasal [Brooks et al., 2002; McGaughran et al., 2002; Vasudevan et al., 2006], Simpson-Golabi-Behmel [Chen et al., 1993], Spondylocostal dysotosis [Park et al., 1993b; Martinez-Frias et al., 1994; Lam et al., 1999; Rodriguez et al., 2004], and Donnai-Barrow syndromes [Donnai and Barrow, 1993; Gripp et al., 1997; Chassaing et al., 2003]. Accordingly, it is reasonable to hypothesize that mutations in the genes, NIPBL, EPNB1, GPC3, and DLL3, responsible for the first four disorders, respectively, interfere with normal diaphragm development or act to disrupt a downstream target.
The importance of monogenic disorders whose phenotypes include CDH can be gleaned from progress in the genetic understanding of another common birth defect, cleft lip ± cleft palate. Specifically, mutations in interferon regulatory factor 6 (IRF6) protein binding and DNA binding domains cause autosomal dominant lip pit or van der Woude syndrome [Kondo et al., 2002]. However, a common variant in IRF6 increases the risk of developing non-syndromic isolated cleft lip ± cleft palate [Zucchero et al., 2004; Scapoli et al., 2005]. It therefore follows that common variants in genes such as NIPBL or EPNB1 could be risk factors for isolated CDH.
Our group is working to identify the gene responsible for the autosomal recessive disorder, Donnai-Barrow syndrome (DBS) [Kantarci et al., 2006b]. CDH is present in more than half of reported individuals; additional phenotypic details are provided in the article in this issue by Dr. Slavotinek. To identify the locus for DBS we recruited a large consanguineous family from the United Arab Emirates and performed linkage analysis to identify regions of identity by descent. Four affected members of this kindred shared a ~17 centimorgan homozygous region that mapped to chromosome 2q23-q31. Microsatellite marker analysis narrowed this region to 17–18 million base pairs using DNA samples from members of the United Arab Emirates kindred, as well as from multiplex kindreds previously published by Donnai and Barrow and Chassaing et al. [Donnai and Barrow, 1993; Chassaing et al., 2003]. Sequencing of candidate genes within this region is underway. We hypothesize that loss of function mutations will be responsible for the multiple anomaly disorder DBS, while missense mutations or functional genetic variants may contribute to the causation of some ofthe individual anomalies found in DBS, including CDH [Kantarci et al., 2006b].
Additional examples of monogenic syndromes associated with CDH are provided in the article by Dr. Slavotinek in this monograph.
There are published reports describing >50 families containing two or more relatives affected with CDH, for which a causative syndrome or chromosome abnormality has not been identified [Butler and Claireaux, 1962; Welch and Cooke, 1962; Scott and Patterson, 1966; Passarge et al., 1968; ten Kate and Anders, 1970; Feingold, 1971; Harberg et al., 1976; Thomas et al., 1976; Crane, 1979; David et al., 1979; Pollack and Hall, 1979; Arad et al., 1980; Wolff, 1980; Gencik et al., 1982; Norio et al., 1984; Czeizel and Kovacs, 1985; Lipson and Williams, 1985; Toriello et al., 1985; Bocian et al., 1986; Toriello et al., 1986; Farag et al., 1989; Hitch et al., 1989; Carmi et al., 1990; Frey et al., 1991; Sripathi and Beasley, 1992; Narayan et al., 1993; Farag et al., 1994; Gibbs et al., 1997; Mitchell et al., 1997; Kufeji and Crabbe, 1999; Manouvrier-Hanu et al., 2000]. As part of our own research over the last five years, we ascertained more than two dozen multiplex families in whom the diagnosis of a syndrome was not established. Additionally, data from The Association of Congenital Diaphragmatic Hernia Research, Advocacy, and Support (CHERUBS- a nonprofit CDH parents support group) show that 2% of the probands in their survey have an affected 1st degree relative. Thus, multiplex CDH families are not difficult to identify and collectively they suggest genetic causation. However, these multiplex kindreds constitute a heterogeneous group, both in terms of the mode of inheritance as well as whether the diaphragmatic defect is isolated or is occurring along with additional major malformations. Use of multiplex families for linkage analysis to identify genes associated with CDH has not been possible to date (aside from the work on DBS just mentioned above). This is due not only to etiologic heterogeneity, but also to the high mortality rate among those affected limiting the availability of DNA samples.
Multiplex CDH kindreds can be categorized as follows:
Approximately 30–40% of cases with CDH have additional major malformations, often involving the cardiovascular, central nervous, musculoskeletal, and/or genitourinary systems. Despite the presence of malformations in multiple organs, the diagnosis of a syndrome or chromosome abnormality cannot be established so these cases are classified as being multiply-malformed or “non-syndromic”. It is reasonable to hypothesize that a mutant gene, either acting alone or in concert with other genetic variants or environmental triggers, is responsible for all the anomalies in a given patient including the CDH. Non-syndromic associations might help identify genes responsible for CDH. Specifically, if cardiovascular malformations (CVMs) and diaphragmatic defects share a common (genetic) etiology then knowledge about genes causing CVMs may provide knowledge about genes causing CDH. As an example, if the group of cardiovascular defects referred to as laterality defects are over-represented among CDH cases, then mutations in laterality genes, such as lefty1 or 2, could receive further scrutiny as candidate genes in future studies of CDH.
Cardiovascular malformations (CVMs) are present in ~10–15% of those cases with non-syndromic CDH, as discussed in detail in the article by Lin et al. in this volume. If all cases, including those with underlying syndromes and chromosome abnormalities are included, then the prevalence of CVM’s rises to 2ndash;40% of cases [Philip et al., 1991; Robert et al., 1997; Migliazza et al., 1999a; Migliazza et al., 1999b; Dillon et al., 2000; Dott et al., 2003; Tonks et al., 2004]. The most common CVMS that co-occur with CDH reflect those found in the general population, such as ventricular septal defect, atrial septal defect, and tetralogy of Fallot. Hypo-plastic left heart syndrome also occurs but is sometimes over-diagnosed since left heart structures can be small due to abnormal hemodynamics caused by a left-sided diaphragm defect. A far more detailed discussion of the type and prevalence of CVMs found in cases with CDH is presented in the article by Lin, Pober and Adatia in this monograph.
The most common CNS anomalies, present in 5–10% of non-syndromic CDH cases, are neural tube defects and hydrocephalus [David and Illingworth, 1976; Dillon et al., 2000; Dott et al., 2003]. Some authors speculate that problems of schisis-fusion or midline instability account for the cooccurrence of CDH and neural tube defects [Czeizel and Vitez, 1981].
A variety of limb defects occur in ~10% of patients with non-syndromic CDH including polydactyly, syndactyly, and reduction defects [Torfs et al., 1992; van Dooren et al., 2003]. Some authors speculate that co-existence of CDH and limb reduction defects reflects abnormal cervical neural crest migration or mutations in specific genes that are important in limb and diaphragm development though no data to support these hypotheses yet exist [McCredie and Reid, 1978; Lerone et al., 1992; Hou and Wang, 1999].
Routine chromosome analysis performed on unselected patients with CDH identifies an abnormality in ~10% of cases [Thorpe-Beeston et al., 1989; Philip et al., 1991; Bollmann et al., 1995; Howe et al., 1996; Faivre et al., 1998; Garne et al., 2002; Tonks et al., 2004]. Some common abnormalities are trisomy 18, tetrasomy 12p, deletion 15q26, deletion 8p23, and + der 22 t(11;22) [Pecile et al., 1990; Howe et al., 1996; Faivre et al., 1998; Lurie, 2003; Borys and Taxy, 2004; Tonks et al., 2004; van Dooren et al., 2004]; a far more exhaustive list is nicely presented in a recent review [Lurie, 2003]. It is currently unknown why larger regions of aneuploidy (trisomy 18 and isochromosome 12p) increase the risk for CDH, and the genetic basis for these associations is not likely to be elucidated in the near future. However, smaller regions of aneuploidy are proving very powerful for gene discovery. An increasing number of subtle chromosome abnormalities are likely to be detected with use of newer technologies, such as array-based comparative genomic hybridization (aCGH).
PKS is a unique disorder in which affected individuals are tissue mosaics for four copies of the short arm of chromosome 12. Two copies of the chromosome 12 short arm belonging to the normal chromosome 12 homologues are present, along with two additional copies of 12p that have formed a supernumerary isochromosome. The isochromosome is not present in all cell lineages. It is rarely identified in a standard blood (lymphocyte) chromosome analysis, though a recent report [Wu et al., 2006] demonstrated 7% lymphocyte isochromosome recovery compared to 90% skin fibro-blast recovery in a characteristically dysmorphic infant who did not have CDH. Among individuals with PKS, isochromosome 12p is detected in varying percentages (ranging from 5 – 100%) in amniocytes, chorionic villi, buccal cells, and skin fibroblasts [Doray et al., 2002].
Mechanisms underlying PKS vary but the isochromosome most often seems to derive from a maternal pre-meiotic or meiotic error accompanied by centromere misdivision. Several studies demonstrate that the detection frequency of the isochromosome declines over time, both in vitro with continued sub-cultures of growing cells and in vivo with advancing patient age.
In the setting of prenatally diagnosed CDH, chromosome 12p targeted-FISH can be an adjunct to routine karyotyping, and may identify PKS cases due to low-level mosaicism. Similarly, array-based comparative genomic hybridization (aCGH) may detect low level mosiacism, possibly even in lymphocytes, and has already been used to establish the diagnosis using DNA extracted from formalin fixed paraffin embedded autopsy tissue [Delahaye et al., 2006]. Systematic application of these newer molecular cytogenetic techniques will be needed before conclusions about their diagnostic utility can be drawn.
Postnatal findings of PKS include a coarse face, temporal alopecia, broad short hands, streaky cutaneous hyper-pigmentation, shortened neck, developmental delay/ mental retardation, and seizures. The frequency of CDH is low, 10–20%, among individuals postnatally diagnosed with PKS [Mathieu et al., 1997; Schaefer et al., 1997]. Among prenatally diagnosed cases, the major malformations likely to suggest the diagnosis include: polyhydramnios, CDH (found in 33%), relatively shortened limbs, CNS anomalies, cranio-facial dysmorphology (which can be appreciated on 3D ultrasound), and fetal edema [Doray et al., 2002]. Phenotypic severity is extremely broad, ranging from multiple malformations incompatible with life to relatively mild medical and developmental abnormalities, possibly due to the 12p tissue mosiacism. There may be under ascertainment of PKS as skin chromosome analysis is not routinely performed on less severely affected individuals.
PKS can be difficult to distinguish from Fryns syndrome [OMIM 229850] solely based on clinical features. CDH can occur in both disorders though occurs more frequently in Fryns syndrome. The occurrence of bilateral CDH is a rarity in either condition, but if present is more suggestive of the diagnosis of Fryns syndrome. Other features that more commonly complicate Fryns syndrome include cleft palate, distal phalangeal and/or nail hypoplasia, cardiovascular malformations, and renal malformations [Slavotinek, 2004]. Features more suggestive of PKS include a high forehead, streaky skin hyper-pigmentation, and sparseness of hair bitemporally [McPherson et al., 1993; Veldman et al., 2002]. It is especially important to perform thorough cytogenetic and molecular cytogenetic testing using the appropriate tissues to confirm or exclude the diagnosis of PKS since this is a sporadic disorder with no known risk of recurrence.
Trisomy 18 is the most common chromosome abnormality detected in all prenatal series of CDH cases. CDH (as well as omphalocele) occurs more often in male trisomy 18 fetuses than in female fetuses; this suggests that males are more likely to be multiply malformed and die in utero which, in turn, could account for the excess of female live births with trisomy 18 [Chen, 2005].
Although both Bochdalek and Morgagni hernias have been reported in trisomy 21, CDH is a relatively low frequency occurrence in trisomy 21. Morgagni hernia seems to be the most common type in trisomy 21 suggesting that three copies of one or more chromosome 21 genes predispose to abnormal development of the anterior portion of the diaphragm [Torfs et al., 1992; Parmar et al., 2001; Marin and Lopoo, 2006].
There are several reports of CDH occurring in infants found to have multiple anomalies with trisomy 22 [Kim et al., 1992; Ladonne et al., 1996]. CDH has also been observed in patients with “partial trisomy 22q” syndrome due to +der 22 t(11;22) (q23.3;q11.2) inherited from a balanced translocation carrier parent [Schinzel et al., 1981; Lin et al., 1986; Kadir et al., 1997]. Taken together, these cytogenetic abnormalities suggest that three copies of one or more genes in distal 22q confers risk for developing CDH, though neither a critical region nor candidate genes have been identified. However, patients who carry +der 22t(11;22) are also trisomic for the distal end of 11q which is further discussed below.
There are several clinical reasons for routine karyotyping: a) to establish the correct diagnosis; b) to provide natural history and prognosis; c) for accurate recurrence risk counseling; and d) to guide prenatal diagnostic testing. The detection of small chromosome abnormalities can inform on these topics but also can identify “hot spots” likely contain genes contributing to CDH. “Hot spots” 15q26.1–q26.2 (DIH1, OMIM 142340), 8p23.1 (DIH2, OMIM 222400) and 8q23 (DIH3, OMIM 610187), are among the bestcharacterized to date and they, as well as selected other hot spots, will be described below.
Almost two dozen unrelated cases with deletion of the 15q26.1 –15q26.2 region share a common phenotype that includes CDH, growth retardation, cardiovascular and limb malformations [Aviram-Goldring et al., 2000; Schlembach et al., 2001; Biggio et al., 2004; Hengstschlager et al., 2004; Klaassens et al., 2005; Slavotinek et al., 2005]. Most of the abnormalities, consisting of de novo deletions, unbalanced reciprocal translocation products and ring chromosomes have been detected with standard chromosome banding techniques. However, several small deletions detected only by aCGH have recently been reported [Slavotinek et al., 2005]. These findings form the basis of the hypothesis that hemizygosity for one or more genes located in 15q26.1 – 15q26.2 confer risk for CDH. Application of careful deletion mapping recently led to the delineation of a ~five megabase CDH critical region containing four candidate genes [Klaassens et al., 2005]. Subsequent analyses suggest a slightly more telomeric location of the critical region containing several candidate genes [Castiglia et al., 2005; Scott et al., 2007], with a particularly compelling candidate being COUP-TFII (Chick Ovalbumin Upstream Promotor Transcription Factor 2, also known as Nuclear Receptor Subfamily 2, Group F, Member 2), a receptor belonging to the steroid/thyroid hormone family. Converging lines of evidence that implicate COUP-TFII hemizygosity as a major risk factor for CDH are: a) recurring cytogenetic abnormalities, detailed above, that result in deletion of COUP-TFII; b) presence of a diaphragmatic hernia in the majority of conditionalCOUP-TFII mutant mice [You et al., 2005], c) the role that COUP-TFII plays in regulation of the retinol pathway, a pathway important for diaphragm development, and d) that COUP-TFII interacts with FOG2, mutations of which cause diaphragmatic abnormalities in humans and mouse models [Ackerman et al., 2005]. To date no mutations have yet been identified in COUP-TFII exons or flanking exonintron boundaries in >150 CDH patients [Slavotinek et al., 2006; Scott et al., 2007]. It remains possible that mutations contributing to CDH lie in COUPTF-II upstream regulatory elements rather than in coding regions, that COUP-TFII acts combinatorially with other genetic or environmental factors, or that it plays a minor role in human CDH causation.
The second most common small chromosome abnormality found in association with CDH is del (8)(p23.1) [Pecile et al., 1990; Hutchinson et al., 1992; Faivre et al., 1998; Borys and Taxy, 2004; Shimokawa et al., 2005; Slavotinek et al., 2005; Lopez et al., 2006]. Among the patients reported to date, CDH has been present in ~20% of cases. Depending on the size of the deleted segment patients also demonstrate developmental delay, cardiovascular malformations, genitourinary malformations, subtle facial dys-morphology, and minor limb anomalies. The smallest deletion characterized at the molecular level in a del 8p23 patient who had CDH is ~3.5 Mb [Shimokawa et al., 2005]. In addition to narrowing the DIH2 critical interval, the patient’s deletion breakpoints lie within two low copy repeats (LCRs) suggesting that meiotic misalignment between homologous LCRs predisposes to this deletion, and therefore is mechanistically similar to other deletion and microdeletion disorders [Lupski, 2006]. GATA4 lies within this region and recent data show that in additional to its importance in cardiac development, Gata4 also plays a role in diaphragm and pulmonary development [Ackerman et al., 2006b; Jay et al., 2006].
Disruption of 8q22-q24 by either translocation or deletion has been reported in several patients with CDH [Harnsberger et al., 1982; Temple et al., 1994; Capellini et al., 1996; Howe et al., 1996], though exact breakpoints were not always provided. These cytogenetic abnormalities, combined with detection of a FOG2 (8q23.1) mutation in a patient with diaphragmatic defect and pulmonary hypoplasia, provide compelling evidence for the importance of this locus.
Wolf-Hirschhorn syndrome is a clinically well-characterized chromosome deletion disorder. Although CDH is an infrequent complication, its documentation in several cases suggests that occurrence of CDH is not due to chance but rather is related to loss of a specific gene or genes in this region [Tachdjian et al., 1992; Howe et al., 1996; Sergi et al., 1998; Tapper et al., 2002; Van Buggenhout et al., 2004; van Dooren et al., 2004; Casaccia et al., 2006; Slavotinek et al., 2006]. Using standard chromosome techniques, variably sized-deletions have been noted in WHS cases, both with and without CDH. Only four cases with CDH have been characterized at the molecular level [Van Buggenhout et al., 2004; van Dooren et al., 2004; Casaccia et al., 2006; Slavotinek et al., 2006], the break point occurring in 4p16.3 in the case with the smallest deletion [Casaccia et al., 2006]. Based on current data, it is not possible to pinpoint the CDH-associated critical region.
Several cases with CDH, plus additional anomalies, have been reported in association with chromosome rearrangements producing disruption or deletion of chromosome band 1q41–q42.12 [Youssoufian et al., 1988; Smith et al., 1994; Rogers et al., 1995; Slavotinek et al., 2006; Kantarci et al., 2006a]. The smallest rearrangement characterized to date is ~5 Mb deletion, and this interval contains 29 candidate genes [Kantarci et al., 2006a]. Further characterization of additional patients with aneuploidy at this locus will be needed before a critical region, or a candidate gene, can be identified.
Trisomy for the qter region of chromosome 11, arising through inheritance of an unbalanced chromosome complement from a balanced translocation carrier parent has been reported in several CDH patients. Most commonly the parent is a carrier for t(11;22) (q23.3;q11.2), but two additional CDH patients whose parents carried t(11;12) and t(11;13) have also been reported [Park et al., 1993a; Klaassens et al., 2006]. The 11q duplication is ~19 Mb in the only patient whose aneuploidy has been characterized at the molecular level [Klaassens et al., 2006].
Two observations which suggest genetic factors play only a small role in the development of CDH, particularly in non-syndromic or isolated cases, merit further discussion. “Precurrence” risk studies show a low rate of clustering of CDH among siblings [David and Illingworth, 1976; Czeizel and Kovacs, 1985; Pober et al., 2005]. Despite a low absolute sibling recurrence in non-syndromic or isolated cases, there is a 20-fold CDH excess in siblings compared to the occurrence rate in the general population. Additionally, the presence of de novo point mutations and cytogenetic aberrations raise the possibility that many cases of CDH are in fact caused by de novo events which would rarely be associated with sibling recurrence.
The second observation questioning the importance of genetic causation in CDH derives from twin studies. Monozygotic (MZ) twin pairs concordant for CDH have been reported, but several MZ pairs discordant for CDH have been published as well (reviewed in [Pober et al., 2005]). However, there are precedents demonstrating that phenotypic discordance in MZ twins does not rule out genetic mechanisms [Machin, 1996; Mansilla et al., 2005], including: de novo dominant gene mutations, deletions or duplications; autosomal recessive mutations (some with incomplete penetrance); multifactorial or 2nd hit mutations; and epigenetic modifications. Furthermore, a contributory role of non-genetic factors, such as stochastic events and environmental exposures, which may be acting synergistically with genetic risk factors is highly likely.
Collectively, the evidence presented in this article strongly support genetic causation in some, if not many, cases of CDH. The evidence is most compelling for syndromic cases of CDH, e.g., patients with multiple anomalies for whom an underlying genetic or chromosome etiology has been established. However, genetic causation is also suggested in cases with isolated CDH, given reports of mouse genetic models, multiplex human families with seemingly isolated CDH, and report of a FOG2 mutation in a patient with apparent non-syndromic CDH. We anticipate that mutations in at least several additional genes, either acting singly or as part of gene-gene or gene-environmental combinations, will be identified as contributing to most cases of CDH. Such genes can then be studied to determine whether they represent different branch points within the same signaling pathways, and furthermore, whether they provide targets for potential therapies.
Grant sponsor: RO1; Grant number: HD55150-01.
NOTE ADDED IN PROOF
A complete review of cytogenetic abnormalities in CDH is in press by Holder AM et al. “Genetic Factors in Congenital Diaphragmatic Hernia” in Am J Hum Genet. Accepted 2/1/07.